Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25
Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $43 to $25.
Read original at benzingaStocks · News reference
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9
JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 4:14 PM
- Checked
- Aug 14, 2026, 4:14 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate
Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the
Read original at benzinga8-K filing — Upstream Bio, Inc. (UPB)
Filed: 2026-08-11 AccNo: 0001193125-26-343407 Size: 401 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar